ReviewDisease models & mechanisms2026
Organoids as brain tumour models: bridging the translational gap.
Review in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Advances in stem cell-derived brain organoids, enabled by the generation of human reprogrammed pluripotent stem cells, have significantly expanded the repertoire of models available for brain tumour research. These approaches have predominantly been applied to glioblastoma and medulloblastoma, leveraging brain region-specific cerebral/cortical or cerebellar organoids, respectively. Organoids have the potential to close the gap between current two-dimensional cell-based brain tumour models and patients, while helping to address the limitations of animal models. In this At a Glance article, we outline current stem cell-derived organoid-based brain tumour models and how they have expanded our understanding of paediatric and adult brain tumours, including their onset, heterogeneity and treatment. We also describe how these organoids are currently being refined toward more accurate, clinically relevant models and highlight future directions to improve their translatability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.